Increased Kidney Glucose Utilization Induced by Cyclosporine:Lack of Relation to Magnesium Excretion

Increased Kidney Glucose Utilization Induced by Cyclospone:Lack of Relation to Magnesium Excretion. BOROWITZ, J. L, MAYER,P. R., RODRIGUEZ, C A., AND ANTOUN, M. (1989).Fundam. Appl Toxicol12, 158–162. Cyclosporine enhances D-[5-³H]glucose utilizationin homogenates of rat kidney medulla but not kidney cortex orliver. This is true whether cyclosporine is added to fresh tissuehomogenates or is given to rats prior to sacrifice. Throughthe use of isolated perfused rat kidneys, an attempt was madeto relate increased glucose utilization by cyclosporine to apossible consequence of cyclosponne nephrotoxicity, viz., lossof magnesium in urine. Although an enhanced rate of glucoseutilization by cyclosporine was evident in isolated kidneys,glucose consumption was not related to urinary magnesium loss.In fact, kidneys from cyclosporine-treated rats actually showeda normal or even diminished urinary magnesium loss. The datasuggest that cyclosporine-induced magnesium imbalance may beextrarenal in origin and that the kidney medulla may be a primarysite of the nephrotoxic action of cyclosporine since the drugincreases glucose utilization at this site.     

胰岛素样生长因子结合蛋白3在非小细胞肺癌中的表达研究

目的:检测胰岛素样生长因子结合蛋白3(IGFBP3)在非小细胞肺癌(NSCLC)组织中的表达,探讨其与肺癌临床病理学特征和生存时间的关系。方法:采用免疫组织化学和免疫印迹技术检测IGFBP3在34例肺鳞癌和25例肺腺癌(共21例含癌旁肺组织)及15例良性肺病变组织中的表达。结果:IGFBP3在良性肺组织中表达定位于细胞质;而在肺癌组织中表达定位于细胞质和细胞核(分别称为IGFBP3质表达和核表达),后二者阳性率为44%(26/59)和29%(17/59)。IGFBP3使表达在肺癌和良性肺组织间差异无统计学意义。在伴有局部淋巴结转移肺癌组织中IGFBP3核表达显著低于无淋巴结转移肺癌组织,P=0.0029;在低分化肺癌组织中IGFBP3核表达显著低于中或高分化肺癌,P=0.0292。IGFBP3质表达与胰岛素样生长因子1(IGF1)在肺癌组织中的表达显著相关,P=0.0007。IGFBP3质表达阳性者预后差,而IGFBP3核表达阳性者预后优于阴性表达者。结论:在NSCLC组织中,IGFBP3质表达可能与调节IGF作用有关,而核表达则可能与抑制肿瘤生长有关,IGFBP3质或核表达具有一定的预后意义。     

THE REGROWTH OF RIGHT ATRIAL NORADRENERGIC NERVES AFTER 6-HYDROXYDOPAMINE IN GENETICALLY DIABETIC MICE: EFFECTS OF INSULIN TREATMENT

1 This study examined the rate of repletion of right atrial noradrenaline levels after a single dose (100 mg/kg i.p.) of 6-hydroxydopamine (6-OH Da) in diabetic and non-diabetic mice of the C57 BL/KS db/db strain. 2 In mice which received no 6-OH Da there was no significant difference, in endogenous noradrenaline levels, between diabetic and non-diabetic animals. The depletion of noradrenaline 24 h after 6-OHDa was slightly more profound in the diabetic mice than in non-diabetic controls. Thereafter the rate of repletion of noradrenaline was more rapid in the diabetic group. 3 The normal noradrenaline content was reinstated in diabetic mice between 7 and 10 days after 6-OHDa. In the non-diabetic group levels similar to those found in untreated mice were not reinstated until 14 days after 6-OHDa. 4 Ten days after 6-OHDa right atria from diabetic mice were markedly more responsive to stimulation of the intramural noradrenergic nerves than were preparations from non-diabetic mice. 5 A group of diabetic mice was treated with insulin (10 m Units/g daily) for 6 weeks. The right atria from these animals, examined 10 days after 6-OHDa, were similar in their responses to noradrenergic nerve stimulation to the preparations from the non-diabetic mice. 6 All these groups of atria gave similar responses to exogenous noradrenaline. These findings indicate that regrowth of noradrenergic terminals after 6-OHDa was more rapid in diabetic mice than in either insulin-treated diabetic mice or non-diabetic mice.